I'm not sure of the accuracy of the figures below, but this from an article in AFR (August 2023) relaying MSB investor belief in the way back to $5:
"400 children a year with steroid refractory acute GVHD. US$400,00 - US$500,000 a treatment. Generate sales of US$200 million a year. Gross margin of 60 per cent. Net profit to Mesoblast US$45 million a year. US Stockmarket healthcare mutliple of 60 (P/E 60).
US$2.7 billion market cap.
Above is not financial advice and my opinion only.
